Screening for malaria antigen and anti-malarial IgG antibody in forcibly-displaced Myanmar nationals: Cox's Bazar district, Bangladesh, 2018.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
30 Mar 2020
Historique:
received: 12 08 2019
accepted: 23 03 2020
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 21 10 2020
Statut: epublish

Résumé

Several refugee settlements in Bangladesh have provided housing and medical care for the forcibly-displaced Myanmar nationals (FDMN, also known as Rohingya) population. The identification of malaria infection status in the refugee settlements is useful in treating infected persons and in developing malaria prevention recommendations. Assays for Plasmodium antigens and human IgG against Plasmodium parasites can be used as indicators to determine malaria infection status and exposure. Dried blood spot (DBS) samples (N = 1239) from a household survey performed April-May 2018 in three settlements in Cox's Bazar district, Bangladesh were utilized for a sample population of children from ages 1-14 years of age. The samples were tested using a bead-based multiplex antigen assay for presence of the pan-Plasmodium antigen aldolase as well as Plasmodium falciparum histidine rich protein 2 (HRP2). A bead-based multiplex assay was also used to measure human IgG antibody response to P. falciparum, Plasmodium malariae, and Plasmodium vivax merozoite surface protein 1 antigen (MSP1) isoforms, and P. falciparum antigens LSA1, CSP, and GLURP-R0. There were no detectable Plasmodium antigens in any samples, suggesting no active malaria parasite infections in the tested children. IgG seroprevalence was highest to P. vivax (3.1%), but this was not significantly different from the percentages of children antibody responses to P. falciparum (2.1%) and P. malariae (1.8%). The likelihood of an anti-Plasmodium IgG response increased with age for all three malaria species. Evidence of exposure to any malaria species was highest for children residing 8-10 months in the settlements, and was lower for children arriving before and after this period of time. Absence of Plasmodium antigen in this population provides evidence that children in these three Bangladeshi refugee settlements did not have malaria at time of sampling. Higher rates of anti-malarial IgG carriage from children who were leaving Myanmar during the malaria high-transmission season indicate these migrant populations were likely at increased risk of malaria exposure during their transit.

Sections du résumé

BACKGROUND BACKGROUND
Several refugee settlements in Bangladesh have provided housing and medical care for the forcibly-displaced Myanmar nationals (FDMN, also known as Rohingya) population. The identification of malaria infection status in the refugee settlements is useful in treating infected persons and in developing malaria prevention recommendations. Assays for Plasmodium antigens and human IgG against Plasmodium parasites can be used as indicators to determine malaria infection status and exposure.
METHODS METHODS
Dried blood spot (DBS) samples (N = 1239) from a household survey performed April-May 2018 in three settlements in Cox's Bazar district, Bangladesh were utilized for a sample population of children from ages 1-14 years of age. The samples were tested using a bead-based multiplex antigen assay for presence of the pan-Plasmodium antigen aldolase as well as Plasmodium falciparum histidine rich protein 2 (HRP2). A bead-based multiplex assay was also used to measure human IgG antibody response to P. falciparum, Plasmodium malariae, and Plasmodium vivax merozoite surface protein 1 antigen (MSP1) isoforms, and P. falciparum antigens LSA1, CSP, and GLURP-R0.
RESULTS RESULTS
There were no detectable Plasmodium antigens in any samples, suggesting no active malaria parasite infections in the tested children. IgG seroprevalence was highest to P. vivax (3.1%), but this was not significantly different from the percentages of children antibody responses to P. falciparum (2.1%) and P. malariae (1.8%). The likelihood of an anti-Plasmodium IgG response increased with age for all three malaria species. Evidence of exposure to any malaria species was highest for children residing 8-10 months in the settlements, and was lower for children arriving before and after this period of time.
CONCLUSIONS CONCLUSIONS
Absence of Plasmodium antigen in this population provides evidence that children in these three Bangladeshi refugee settlements did not have malaria at time of sampling. Higher rates of anti-malarial IgG carriage from children who were leaving Myanmar during the malaria high-transmission season indicate these migrant populations were likely at increased risk of malaria exposure during their transit.

Identifiants

pubmed: 32228699
doi: 10.1186/s12936-020-03199-4
pii: 10.1186/s12936-020-03199-4
pmc: PMC7106647
doi:

Substances chimiques

Antibodies, Protozoan 0
Antigens, Protozoan 0
HRP-2 antigen, Plasmodium falciparum 0
Immunoglobulin G 0
Protozoan Proteins 0
Fructose-Bisphosphate Aldolase EC 4.1.2.13

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

130

Références

Infect Immun. 2008 Apr;76(4):1748-55
pubmed: 18212081
Clin Vaccine Immunol. 2016 Jul 05;23(7):546-54
pubmed: 27053629
BMC Med. 2014 Sep 09;12:150
pubmed: 25199532
J Infect Dis. 2019 Jan 9;219(3):437-447
pubmed: 30202972
Acta Trop. 2005 Sep;95(3):233-47
pubmed: 16055071
Immunol Lett. 1994 Jul;41(2-3):115-20
pubmed: 8002025
PLoS Negl Trop Dis. 2018 Feb 14;12(2):e0006278
pubmed: 29444078
Malar J. 2015 Sep 04;14:338
pubmed: 26337785
Trans R Soc Trop Med Hyg. 2004 Jul;98(7):438-41
pubmed: 15138082
Lancet Glob Health. 2014 Feb;2(2):e98-105
pubmed: 25104666
Malar J. 2011 Dec 13;10:357
pubmed: 22165959
Lancet Infect Dis. 2018 Jun;18(6):609-610
pubmed: 31272735
J Infect Dis. 2014 Oct 1;210(7):1115-22
pubmed: 24719471
Am J Trop Med Hyg. 2017 Feb 8;96(2):312-318
pubmed: 27895279
Malar J. 2010 Jan 14;9:15
pubmed: 20074326
Malar J. 2018 Nov 9;17(1):417
pubmed: 30413163
J Infect Dis. 2014 Oct 1;210(7):1123-32
pubmed: 24737801
Infect Immun. 2015 Feb;83(2):646-60
pubmed: 25422270
BMC Res Notes. 2017 Sep 8;10(1):472
pubmed: 28886727
J Infect Dis. 2018 Feb 14;217(5):685-692
pubmed: 29220497
Sci Total Environ. 2016 May 15;553:458-465
pubmed: 26933968

Auteurs

Austin Lu (A)

Georgia State University, Atlanta, GA, 30302, USA.

Olivia Cote (O)

Georgia Institute of Technology, Atlanta, GA, 30332, USA.

Silvia D Dimitrova (SD)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Synergy America, Inc., Duluth, GA, 30097, USA.

Gretchen Cooley (G)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

A Alamgir (A)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

M Salim Uzzaman (MS)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

Meerjady Sabrina Flora (MS)

Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.

Yulia Widiati (Y)

United Nations Children's Fund, Motel Road, Cox's Bazar, 4700, Bangladesh.

Mohammad Saifuddin Akhtar (MS)

United Nations Children's Fund, Motel Road, Cox's Bazar, 4700, Bangladesh.

Maya Vandenent (M)

United Nations Children's Fund, 1 Minto Road, Dhaka, 1000, Bangladesh.

Daniel C Ehlman (DC)

Global Immunization Division, Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Sarah D Bennett (SD)

Global Immunization Division, Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Leora R Feldstein (LR)

Global Immunization Division, Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Eric Rogier (E)

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA. erogier@cdc.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH